Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT06325592
Other study ID # REHSIL2023V1.1
Secondary ID
Status Completed
Phase
First received
Last updated
Start date October 1, 2023
Est. completion date March 1, 2024

Study information

Verified date March 2024
Source Sichuan Cancer Hospital and Research Institute
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study aimed to analyze perioperative information in patients with high-grade squamous intraepithelial lesion (HSIL) undergoing total hysterectomy (TH), offering insights into optimal surgery timing, selecting the operation path, and enhancing surgical operation details.


Recruitment information / eligibility

Status Completed
Enrollment 826
Est. completion date March 1, 2024
Est. primary completion date March 1, 2024
Accepts healthy volunteers No
Gender Female
Age group N/A and older
Eligibility Inclusion Criteria: - patients were confirmed with HSIL through pathology at our hospital or another tertiary facility, with additional confirmation via pathological consultation at our facility; - LH or abdominal hysterectomy (AH) +/- bilateral fallopian tube or bilateral adnexectomy was performed after LEEP; - the patient had no history of systemic malignancies. Exclusion Criteria: - severe medical and surgical complications; - an extensive or subextensive hysterectomy was performed; - surgical removal scope involving tissues (such as lymph nodes) or organs (such as the appendix) other than the uterus, ovaries, and fallopian tubes; - fever symptoms within the last month; - incidence of pelvic and abdominal infections, vaginitis, or similar conditions within the past month.

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
surgical timing and operation path
surgical timing; laparoscopic hysterectomy or abdominal hysterectomy

Locations

Country Name City State
China Sichuan Cancer Hospital and Research Institute Chengdu Sichuan

Sponsors (1)

Lead Sponsor Collaborator
Sichuan Cancer Hospital and Research Institute

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Postoperative fever Use a thermometer to measure your temperature Within 7 days of surgery
Primary Postoperative therapeutic use of antibiotics Postoperative therapeutic use of antibiotics Within 7 days of surgery
Secondary Postoperative complications Postoperative complications Within 7 days of surgery
Secondary Postoperative hospitalization days Postoperative hospitalization days Date of surgery to date of discharge
Secondary Postoperative hemoglobin Postoperative hemoglobin Within 7 days of surgery
Secondary Postoperative white blood cell count Postoperative white blood cell count Within 7 days of surgery
Secondary Postoperative erythrocyte count Postoperative erythrocyte count Within 7 days of surgery
Secondary Postoperative albumin number Postoperative albumin number Within 7 days of surgery
Secondary Postoperative CRP value Postoperative CRP value Within 7 days of surgery
See also
  Status Clinical Trial Phase
Completed NCT04177641 - Evaluation of Thioldisulfide Balance in Cervical Preinvasive Lesions
Recruiting NCT05210348 - Clinical Evaluation of Detection of High Risk HPV in Urine
Not yet recruiting NCT04115787 - Conservative Management in Patients Diagnosed With Grade 2 or Grade 3 CIN
Active, not recruiting NCT02576561 - Safety and Efficacy Study of TVGV-1 Vaccine to Treat HPV Induced Cervical HSIL Phase 2
Active, not recruiting NCT05613283 - Primary Cervical Cancer Screening by Self-sampling HPV Test
Not yet recruiting NCT06333743 - Laser Ablation in the Treatment of High-grade Cervical Lesions N/A
Completed NCT03920800 - Preventing Invasive Cervical Cancer: The Importance of Expectant Management in Young Women With High-grade Pre-cancerous Lesions
Completed NCT03239223 - Study of Topical ABI-1968 in Subjects With Precancerous Cervical Lesions From Human Papillomavirus (HPV) Infection Phase 1
Not yet recruiting NCT06233331 - Use of ACU-D1 in HPV Associated Vulvar and Perianal Lesions in People With HIV Phase 1